ArticleDiabetology & metabolic syndrome2025
The association between metabolic syndrome and incidence of endometrial cancer: a meta-analysis.
Article in Diabetology & metabolic syndrome, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetabolic syndrome (MetS), a cluster of metabolic abnormalities, has been increasingly linked to hormone-related cancers, including endometrial cancer (EC). However, the overall magnitude and consistency of this association remain unclear. We performed a meta-analysis to evaluate whether MetS is associated with an increased incidence of EC in women.
methodsPubMed, Embase, and Web of Science were systematically searched from inception to June 8, 2025. Eligible studies were longitudinal cohort or nested case-control studies that reported the association between baseline MetS and incident EC in the general female population. Risk ratios (RRs) and 95% confidence intervals (CIs) were pooled using a random-effects model accounting for possible influence of heterogeneity.
resultsNine studies involving 11 datasets and over 9.1 million women were included. MetS was associated with a significantly increased risk of EC (pooled RR = 2.00, 95% CI: 1.67–2.40, p < 0.00001; I² = 93%). The association was stronger in prospective cohort and nested case-control studies (RR = 2.30 and 2.02, respectively) than in retrospective cohort studies (RR = 1.42; p for subgroup difference < 0.001). The results were not significantly affected by menopausal status of the women, diagnostic criteria of MetS, follow-up durations, EC validation methods, or study quality scores (p-values for subgroup difference all > 0.05).
conclusionsMetS is associated with a two-fold increased risk of EC in women. These findings underscore the importance of metabolic health management in strategies for EC prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.